lorecivivint
Small moleculeexperimental
Clinical trial activity
12 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
9
Phase 3
5
Phase 4
0
Earliest trial started Mar 1, 2014 (NCT02095548)
Timeline
Indications
Mechanism of action
- Dual specificity protein kinase CLK2INHIBITOR
CLK2 inhibitor
Dual specificity tyrosine-phosphorylation-regulated kinase 1A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)CC(=O)Nc1cncc(-c2ccc3[nH]nc(-c4nc5cncc(-c6cccc(F)c6)c5[nH]4)c3c2)c1- Mol. weight
- 505.56 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297639 ↗
Also known as
- sm04690
- sm04690
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05603754 | Phase 3 | Nov 18, 2022 | Biosplice Therapeutics, Nordic Bioscience |
| NCT04931667 | Phase 3 | Jul 15, 2021 | Biosplice Therapeutics |
| NCT04598542 | Phase 1 | Oct 13, 2020 | Biosplice Therapeutics |
| NCT04520607 | Phase 3 | Aug 25, 2020 | Biosplice Therapeutics |
| NCT04385303 | Phase 3 | May 31, 2020 | Biosplice Therapeutics |
| NCT03928184 | Phase 3 | May 17, 2019 | Biosplice Therapeutics |
| NCT03706521 | Phase 2 | Apr 11, 2019 | Biosplice Therapeutics |
| NCT03727022 | Phase 2 | Nov 28, 2018 | Biosplice Therapeutics |
| NCT03246399 | Phase 1 | Jul 26, 2017 | Biosplice Therapeutics |
| NCT03122860 | Phase 2 | Apr 24, 2017 | Biosplice Therapeutics |
| NCT02536833 | Phase 2 | Aug 1, 2015 | Biosplice Therapeutics |
| NCT02095548 | Phase 1 | Mar 1, 2014 | Biosplice Therapeutics |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biosplice Therapeutics | For profit | 12 | 12 | 3 | 2014 |
| Nordic Bioscience | For profit | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1